3月20日收盘后,中国生物制药(01177.HK,股价3.7港元,市值694.48亿港元)发布2024年年度业绩公告。公司去年实现营业收入288.7亿元,同比增加10.2%;实现归属于母公司持有者盈利35亿元,同比增长50.1%。作为传统药企转型代表,中国生物制药及附属公司去年共有6个创新产品获中国国家药品监督管理局(NMPA)批准上市,其中4个为国家1类创新药,年报显示,公司“是2024年获批1...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.